Final Report of the Safety Assessment of Hyaluronic Acid, Potassium Hyaluronate, and Sodium Hyaluronate

International Journal of Toxicology

Volumn 28, Issue 4_suppl, 2009, Pages 5-67

  Becker, Lillian C ^a   Bergfeld, Wilma F ^a   Belsito, Donald V ^a   Klaassen, Curtis D ^a   Marks, James G ^a   Shank, Ronald C ^a   Slaga, Thomas J ^a   Snyder, Paul W ^a   Andersen, F Alan ^a  

^a Cosmetic Ingredient Review ^*  (United States)

Author keywords

cosmetics; hyaluronic acid; safety

Indexed keywords

AGENTS ACTING ON THE EYE; ANTIOXIDANT; COSMETIC; GLUCURONIC ACID; HYALURONIC ACID; N ACETYLGLUCOSAMINE; ORGANIC SOLVENT; POLYMER; POTASSIUM SALT; SODIUM;

ACUTE TOXICITY; AEROSOL; ANALYTIC METHOD; ARTICLE; BACTERIUM; BIOLOGICAL FUNCTIONS; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CARBOHYDRATE ABSORPTION; CARBOHYDRATE METABOLISM; CARBOHYDRATE SYNTHESIS; CARCINOGENICITY; CHEMICAL STRUCTURE; CHRONIC TOXICITY; CLINICAL ASSESSMENT; CROSS LINKING; CYTOTOXICITY; DEVELOPMENT; DEVELOPMENTAL TOXICITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG IMPURITY; DRUG SAFETY; EXCRETION; EYE TOXICITY; FERMENTATION; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; HALF LIFE TIME; HUMAN; IMMUNOGENICITY; IMMUNOLOGY; INFECTION CONTROL; INFLAMMATION; INHALATION; LUNG TOXICITY; MOLECULAR WEIGHT; NEUROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OTOTOXICITY; PHOTOREACTIVITY; PLEURA CAVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE TOXICITY; RESPIRATORY FUNCTION; RISK ASSESSMENT; SKIN ABSORPTION; SKIN IRRITATION; SKIN SENSITIZATION; SURGERY; TRANSPLANTATION; VESICOURETERAL REFLUX; WATER RETENTION; ANIMAL; CHEMISTRY; TOXICITY TESTING;

ANIMALS; COSMETICS; HYALURONIC ACID; POLYMERS; TOXICITY TESTS;

EID: 70349776546     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809337738     Document Type: Article

References (305)

1. Balazs EA, Laurent TC, Howe AF, Varga L. Irradiation of mucopolysaccharides with ultraviolet light and electrons. Rad Res. 1959; 11: 149.
2. Laurent TC Biochemistry of hyaluronan. Acta Otolaryngol. 1987;Suppl 442: 7-24.
3. Laurent TC, Laurent UBG, Fraser JRE Functions of hyaluronan. Ann Rheum Dis. 1995; 54: 429-432.
4. Hascall VC, Laurent TC Hyaluronan: structure and physical properties. 1997. Available at: http://www.glycoforum.gr.ip/science/hyaluronan/HA01/HA01E.html. Accessed February 21, 2005.
5. Sheehan JK, Gardner KH, Atkins ED Hyaluronic acid: a double-helical structure in the presence of potassium at low pH and found also with the cations ammonium, rubdium and caesium. J Molec Biol. 1977; 117: 113-135.
6. Tan SW, Johns MR, Greenfield PF Hyalruonic acid: a versatile biopolymer. Aust J Biotech. 1990; 4: 38-43.
7. Gottschalk TE, NcEwen GN Jr. International Cosmetic Ingredient Dictionary and Handbook. Washington, DC; CTFA; 2006.
8. Billek G., Billek D. Hyaluronic acid: the history of an active ingredient in cosmetics [in German]. Parfuem Kosmet. 1988; 69: 788-790; 792-795.
9. Sutherland IW Novel and established applications of microbial polysaccharides. Trends Biotechnol. 1998; 16: 41-46.
10. Laurent TC Structure of Hyaluronic Acid. New York, NY: Academic Press; 1970.
11. Ogston AG The Biological Functions of the Glycosaminoglycans. New York, NY: Academic Press; 1970.
12. Comper WD, Laurent TC Physiological function of connective tissue polysaccharides. Phyil Rev. 1978; 58: 255.
13. Balazs EA, Band P. Hyaluronic acid: its structure and use. Cosmetics & Toiletries. 1984; 99: 65-72.
14. Morris ER, Reese DA, Welsh EJ Conformation and dynamic interactions in hyaluronate solutions. J Molec Biol. 1980; 138: 383.
15. Cleland RL, Wang JL, Detweiler DM Polyelectrolyte properties of sodium hyaluronate. 2: potentiometric titration of hyaluronic acid. Macromolecules J. 1982; 15: 386-395.
16. Balazs EA, Laurent TC Viscosity function of hyaluronic acid as a polyelectrolyte. J Polym Sci. 1951; 6: 665-667.
17. Cleland RL Comparison of polyelectrolyte behaviour of hyaluronate with that of carboxymethyl cellulose. Biopolymers. 1968; 6: 1519-1529.
18. Scott JE, Cummings C., Brass A., Chen Y. Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowing-electron microscopy and computer simulation. Biochem J. 1991; 274: 699-705.
19. Scott JE Secondary and tertiary structures of hyaluronan in aqueous solution: some biological consequences. 1998. Available at: http://www.glucoforum.gr.jp/science/hyaluronan/HA02/HA02E.html. Accessed February 21, 2005.
20. Lower E. Heralding hyaluronic acid. Soap Perfum Cosmet. 1998; 71: 41-42.
21. Denlinger JL, Balazs EA Replacement of the liquid vitreous with sodium hyaluronate in monkeys. I: short-term evaluation. Exp Eye Res. 1980; 31: 80-99.
22. Milas M., Rinaudo M., Fouissac E. Molecular weight and rheotological measurements of sodium hyaluronate. Cosmetics & Toiletries. 1993; 108: 57-63.
23. Cleland RL, Stoomiller AC, Roden L., Laurent TC Partial characterization of reaction products formed by the degradation of hyaluronic acid with ascorbic acid. Biochim Biophy Acta. 1969; 192: 385.
24. Duranti F., Galti G., Bovani B., Calandra M., Rosati ML Injectable hyaluronic acid gel for soft tissue augmentation: a clinical and histological study. Dermatol Surg. 1998; 24: 1317-1325.
25. Hyaluronic acid and sodium hyaluronate: sources, molecular weight and protein content. 2006. Unpublished data from CTFA; 2/23/06; 1p.
26. Kendall FE, Heidelberger M., Awson MH Serologically inactive polysaccharide elaborated by mucoid strains of group A Hemolytic streptococci. J Biol Chem. 1937; 118: 61-69.
27. Meyer D., Dubos R., Smyth EM The hydorlysis of the polysaccharide acids of vitreous humor, umbilical cord and Streptococcus by aurolytic enzyme of pneumococcus. J Biol Chem. 1937; 118: 71-78.
28. Seastone CV Virulence of group C hemolytic streptococci of animal origin. J Exp Med. 1939; 70: 361-378.
29. Kjems E., Lebech K. Isolation of hyaluronic acid from cultures of Streptococci in a chemically defined medium. Acta Pathol Microbiol Scand B. 1976; 84: 162-164.
30. Sugahara K., Schwarts NB, Dorfman A. Biosynthesis of hyaluronic acid by Streptococcus. J Biol Chem. 1979; 254: 6252-6261.
31. Akasaka HSS, Setu M., Yanagi M., Fukushima S., Mitusui TJ Industrial production of hyaluronic acid by Streptococcus zooepidemicus [in Japanese]. Soc Cosmet Chem Jpn. 1988; 22: 35-42.
32. Rapport MM, Linker A., Meyer K. The hydrolysis of hyaluronic acid by pneumococcal hyaluronidase. J Biol Chem. 1951; 192: 283-291.
33. MacLennan AP The production of capsules, hyaluronic acid and hyaluronidases by group A and C Streptococci. J Gen Microbiol. 1956; 14: 134-142.
34. MacLennan AP The isolation and characterization of a hyaluronidase produced by a capsulated strain of a group C Streptococci. J Gen Microbiol. 1956; 14: 143-152.
35. MacLennan AP The production of capsules, hyaluronic acid and hyaluronidase by 25 strains of group C Streptococci. J Gen Microbiol. 1956; 15: 485-491.
36. Warren GH, Gray J. Isolation and purification of Streptococal hyaluronic acid. Proc Soc Exp Biol Med. 1959; 102: 125-127.
37. Warren GH, Gray J. Production of a polysaccharide by Staphylococcus aureus III: action of penicillin and polysaccharide on enzymic lysis. Proc Soc Exp Biol Med 1965; 118: 627-631.
38. Balazs EA Hyaluronate-based compositions and cosmetic formulations containing same. US Patent No. 4,303,676. 1981.
39. Balazs EA, Leschiner A. Hyaluronan, its crosslinked derivative hylan and their medical applications. In: Inagaki H, Phillips GO, eds. Cellulosics Utilization: Research and Rewards in Cellulosics (Proceedings of Nisshinbo International Conference on Cellulosics Utilization in the Near Future). New York: Elsevier Applied Science; 1989: 223-241.
40. Micheels P. Human anti-hyaluronic acid antibodies: is it possible.? Dermatol Surg. 2001; 27: 185-191.
41. Piacquadio DJ, Larsen NE, Denlinger JL Hylan b gel (Hylaform) as a soft tissue augmentation material. In: Klein, AW, ed. Tissue Augmentation in Clinical Practice: Procedures and Techniques. New York: Marcel Dekker; 1998: 269-291.
42. Manna F., Dentini M., Desideri P., De Pitá O., Mortilla E., Maras B. Comparative chemical evaluation of two commercially available derivatives of hyaluronic acid (Hylaform from roster combs and Restylane from streptococcus) used for soft tissue augmentation. J Eur Acad Dermatol Venerol. 1999; 13: 183-192.
43. Goldberg VM, Coutts RD Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthoped. 2003; 4: 130-137.
44. Laurent UBG, Tengblad A. Determination of hyaluronate in biological samples by a specific radioassay technique. Anal Biochem. 1980; 109: 386-394.
45. Girard N., Delpech A., Delpech B. Characterization of hyaluronic acid on tissue sections with hyaluronectin. J Histochem Cytochem. 1986; 34: 539-541.
46. Lindner JS, Huang SS Low-angle laser light scattering (LALLS) of macromolecules. In: Barth, HG, Mays, JW, eds. Modern Methods of Polymer Characterization. New York: John Wiley & Sons; 1991: 313-375.
47. Balazs EA, Freeman MI, Klöti R., Meyer-Schwickerath G., Regnault F., Sweeney DB Hyaluronic acid and replacement of vitreous and aqueous humor. Mod Probl Ophthalmol. 1972; 10: 3-21.
48. Delpech B., Bertrand P., Maingonnat C. Immunoenzymoassay of the hyaluronic acid-hyaluronectin interaction: application to the detection of hyaluronic acid in serum of normal subjects and cancer patients. Anal Biochem. 1985; 149: 555-565.
49. Glasser DB, Edelhouser HF Toxicity of surgical solutions. Int Ophthalmol. 1989; 29: 179-187.
50. Filion MC, Phillips NC Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J Pharmacy Pharmacol. 2001; 53: 555-561.
51. World Health Organization (WHO). Epidemic and pandemic alert and response (EPR): avian influenza frequently asked questions. 2005. Available at: http://www.who.int/csr/disease/avian-influenza/avian-faqs/en/index.html. Accessed March 31, 2006.
52. Food and Drug Administration (FDA). Frequency of use of cosmetic ingredients. FDA Database. Washington, DC: FDA; 2005.
53. Cosmetic, Toiletry, and Fragrance Association (CTFA). Concentration of use hyaluronic acid, sodium hyaluronate and potassium hyaluronate. 2005. Unpublished data from CTFA; 11/15/2005; 6 p.
54. Casado FJ, Nusimovich AD LMW hyaluronic acid to induce epidermal regeneration. Drug Cosm Ind. 1991; 148: 30-34, 74.
55. Ministry of Health, Labour and Welfare (MHLW). MHLW notification no. 331 of 2000, as amended on March 23, 2005. Tokyo, Japan: Ministry of Health Labour and Welfare, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau; 2005.
56. European Economic Community (EEC). EEC Cosmetic Directive 76/768/EEC, as amended, Annexes I through VII. Brussells: EEC; 2001.
57. Jensen PA, Obrien D. Industrial Hygiene. John Wiley and Sons Inc: New York, NY; 1993.
58. Bower D. Unpublished information on hair spray particle sizes. Presented at: CIR Expert Panel meeting; September 9, 1999; Washington, D.C.
59. Håkansson L., Hällgren R., Venge P., Artursson G., Vedung S. Hyaluronic aid stimulates neutrophil function in vitro and in vivo: a review of experimental results and a presentation of a preliminary clincal trial. Scand J Infect Dis. 1980;Suppl 24: 54-57.
60. Håkansson L., Hällgren R., Venge P. Effect of hyaluronic acid on phagocytosis of opsonized latex particles. Scand J Immunol. 1980; 11 (6): 649-653.
61. Liu H., Mao J., Yao K., Yang G., Cui L., Cao Y. A study on a chitosan-gelatin-hyaluronic acid scaffold as artificial skin in vitro and its tissue engineering applications. J Bio-mater Sci Polymer Ed. 2004; 15: 25-40.
62. Ritt MJF, Hillebrand-Haverkort ME, ten Veen JH Local treatment of facial lipdystrophy in patients receiving HIV protease inhibitor therapy. Acta Chirurgiae Plasticae. 2001; 43: 54-56.
63. Espallargues M., Pons JM Efficacy and safety of viscosupplementation with hylan G-F 20 for the treatment of knee osteoarthritis. Int J Tech Assess Health Care. 2003; 19: 41-56.
64. Kelly MA, Moskowitz RW, Lieberman JR Hyaluronan therapy: looking toward the future. Amer J Orthopedics. 2004; 33: 23-28.
65. Özgenel GY Effects of hyaluronic acid on peripheral nerve scarring and regenration in rats. Microsurgery. 2003; 23: 575-581.
66. Polack FM, McNiece MT The treatment of dry eyes with Na Hyaluronate (Healon): a preliminary report. Cornea. 1982; 1: 133.
67. Camber O., Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharm Suec. 1985; 22: 315-320.
68. Lüke C., Dietlein T., Jacobi P., Konen W., Drieglstein GK Intracorneal inclusion of high-molecular-weight sodium hyaluronate following detachment of Descemet's membrane during viscocanalostomy. Cornea. 2000; 19: 556-557.
69. Artola A., Alió JL, Bellot JL, Ruiz JM Protective properties of viscoelastic substances (sodium hyaluronate and 2% hydroxymethylcellulose) against experimental free radical damage to the corneal endothelium. Cornea. 1993; 12: 109-114.
70. Percival SPB Results of a clinical trial of sodium hyaluronate in lens implantation surgery. Am Intraocular Implant Soc. 1985; 11: 257-259.
71. Glasser DB, Matsuda M., Edelhouser HF A comparison of the efficacy and toxicity of and intraocular pressure response to viscous solutions in the anterior chamber. Arch Ophthalmol. 1986; 104: 1819-1824.
72. Donnelly MJ, Hohen LT, Clark GM Initial investigation of the efficacy and biosafety of sodium hyaluronate (Healon) as an aid to electrode array insertion. In: Clark GM, Cowan RS, eds. The International Cochlear Implant, Speech, and Hearing Symposium, 1994. Ann Otol Rhinol Laryngol. 1995; 89: 45-48.
73. Stenfors L-E., Berghem GD, Bloom GD, Helström S., Söderberg O. Exogenous hyaluronic acid (Healon) accelerates the healing of experimental myringotomies. Auris-Nasus-Larynx (Tokyo). 1985;Suppl 1: 217-218.
74. Laurent C., Söderberg O., Anniko M., Harwig S. Repair of chronic tympanic membrane perforations using applications of hyaluronan or rice papers prostheses. J Oto-Rhino-Laryngology Rel Specialities. 1991; 53: 37-40.
75. Krauss MC Recent advances in soft tissue augmentation. Seminars Cutaneous Med Surg. 1999; 18: 119-128.
76. Fujishiro M., Yahagi N., Kashimyra K., et al. Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy. 2004; 36: 579-583.
77. Matsui Y., Inomata M., Izumi K., Sonoda K., Shiraishi N., Kitano S. Hyaluronic acid stimulates tumor-cell proliferation at wound sites. Gastrointestinal Endoscopy. 2004; 60: 539-543.
78. Stevens MF, Hoppe M., Holthusen H., Lipfert P. Tetrodotoxin-induced conduction blockade is prolonged by hyalruonic acid with and without bupivacaine. Acta Anaesthesiol. 2004; 48: 128-134.
79. Cantor JO, Turino GM Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema.? Chest. 2004; 125: 288-292.
80. McDermott ML, Edelhouser HF Drug binding of opthalmic viscoelastic agents. Arch Ophthalmol. 1989; 107: 261-263.
81. Park S., Kim JK, Suh H. Evaluation of antibiotic-loaded collagen-hyaluronic acid matrix as a skin substitute. Biomaterials. 2004; 25: 3689-3698.
82. Moroi Y., Fujita S., Fukagawa S., et al. Clinical evaluation of allogenic cultured dermal substitutes for intractable skin ulcers after tumor resection. Eur J Dermatol. 2004; 14: 172-176.
83. FDA Synvisc premarket approval application: summary of safety and effectiveness data. 2000. Available at: http://www.fda.gov/edrh/pdf/p940015.html. Accessed January 5, 2005.
84. FDA Summary of safety and effectiveness data: Nuflexxa. 2004. Available at: http://www.fda.gov/cdrh/mda/docs/p010029.html. Accessed January 5, 2005.
85. FDA New device approval Restylane injectable gel: P020023. 2004. Available at: http://www.fda.gov/fdac/departs/2004/204upd.html. Accessed January 5, 2005.
86. Ramos-e-Silva M., Ribeiro de Castro MC Hyaluronic acid in office practice. Cosmetic Dermatol Update. 2004;May/June: 163-164.
87. Fraser JRE, Laurent TC, Laurent UBG Hyaluronan: its nature, distribution, functions and turnover. J Intern Med. 1997; 242: 27-33.
88. United States Environmental Protection Agency (US EPA). Exposure Factors Handbook. 1997. Available at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=12464&CFIC=1017888&CFTOKEN=55097998. Accessed June 12, 2006.
89. West DC, Hampson IN, Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science. 1985; 228: 1324-1326.
90. Brecht M., Mayer U., Schlosser E., Prehm P. Increased hyaluronate synthesis is required for firoblast detachment and mitosis. Biochem J. 1986; 239: 445-450.
91. Kakehi K., Kinoshita M., Yasueda S. Hyaluronic acid: separation and biological implications. J Chromatography. 2003; 797: 347-355.
92. Spicer AP, McDonald JA Eukaryotic hyaluronan syntheses. 1998. Available at: http://www.glycoforum.gr.jp/science/hyaluronan/HA07/HA07E.html. Accessed January 5, 2005.
93. Szirmai JA Effect of steroid hormones on the glycosaminoglycans of target connective tissues. In: Balazs EA, Jeanloz RW, eds. The Amino Sugars. 1965;11b: 129-154.
94. Pearce RH, Grimmer BJ The Nature of the Ground Substance. New York, NY: Appleton; 1970.
95. Balazs EA, Gibbs DA The Rheological Properties and Biological Function of Hyaluronic Acid. New York, NY: Academic Press; 1970.
96. Yates JR Mechanism of Water Uptake by Skin. New York, NY: Wiley Interscience; 1971.
97. Laurent TC, Laurent UBG, Fraser JRE Serum hyaluronan as a disease marker. DUODECIM Ann Med. 1996; 28: 241-253.
98. Balazs EA Sodium Hyaluronate and Viscosurgery. New York, NY: John Wiley & Sons; 1983.
99. Balazs EA Viscosurgery in the eye. Ocular Inflammation Ther. 1983; 1: 91-92.
100. Laurent TC, Pietruszkiewics A. The effect of hyaluronic acid on the sedimentation rate of other substances. Biochem Biophys Acta. 1961; 49: 258.
101. Balazs EA, Darzynkiewewics Z. The effect of hyaluronic acid on fibroblast, mononuclear phagocytes and lymphocytes. New York, NY: Academic Press; 1972.
102. Forrester JV, Wilkinson PC Inhibition of leucocyte locomotion by hyaluronic acid. J Cell Sci. 1981; 48: 315.
103. Toole BP Development role of hyaluronante. Conect Tissue Res. 1982; 10: 93.
104. Forrester JV, Lackie JM Effect of hyaluronic acid on neutrophil adhesion. J Cell Sci. 1981; 50: 329-344.
105. Pisko EJ, Turner RA, Soderstrom LP, Panetti M., Foster SL, Treadway WJ Inhibition of neutrophil phagocytosis and energy release by hyaluronic acid. Clin Exp Rheumatol. 1983; 1: 41.
106. Dahlgren C., Björkstén B. Effect of hyaluronic acid on polymorphonuclear leucocyte cell surface properties. Scand J Haemotol. 1982; 28: 376-380.
107. Greco RM, Iocono JA, Ehrlich HP Hyaluronic acid stimulates human fibroblast proliferation within a collagen matrix. J Cell Physiol. 1998; 177: 465-473.
108. Prince CW Roles of hyaluronan in bone resorption. BMC Musculoskeletal Disorders. 2004; 5: 12-14.
109. Shepard S., Becker H., Hartmann JX Using hyaluronic acid to create a fetal-like environment in vitro. Annals Plastic Surg. 1996; 36: 65-69.
110. Iocono JA, Ehrlich HP, Keefer KA, Krummel TM Hyaluronan induces scarless repair in mouse limb organ culture. J Ped Surg. 1998; 33: 564-567.
111. Weigel PH, Fuller GM, LeBoeuf RD A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J Theor Biol. 1986; 119: 219-234.
112. Tammi R., Tammi M. Hyaluronan in the epidermis. 1998. Available at: http://www.glcoforum/gr.jp/science/hyaluronan/HA04/HA04E.html. Accessed January 5, 2005.
113. Toole BP, Gross J. The extracellular matrix of the regenerating new limb: synthesis and removal of hyaluronate prior to differentiation. Develop Biol. 1971; 25: 57.
114. Toole BP, Underhill CB Regulation of morphogenesis by the pericellular matrix. In: Yamada KM, ed. Cell Interactions and Development. New York, NY: John Wiley & Sons; 1983: 203.
115. Bychkov SM, Kuz'mina SA. Role of glycosaminoglycans and proteoglycans in erythrocyte aggregation and adhesion. Bull Eksp Biol Med. 1997; 83: 284-288.
116. Knudson CB, Toole BP Changes in the pericellular matrix during differentiation of limb bud mesoderm. Develop Biol. 1985; 112: 308-318.
117. Salustri A., Fulop C. The role of hyaluronan during ovulation and fertilization. 1998. Available at: http://www.glycofourm.gr.jp/science/hyaluronan/HA03/HA03E.html. Accessed January 5, 2005.
118. Sliwa L. Hyaluronic acid and chemoattractant substance from follicular fluid: in vitro effect of human sperm migration. Adv Reprod. 1999; 3: 113-115.
119. Turley EA, Noble PW, Bourguignon LY Signaling properties of hyaluronan receptors. J Biol Chem. 2002; 277: 4581-4584.
120. Toole BP Glycosaminoglycans in Morphogenesis. New York, NY: Plenum Publ; 1981.
121. Toole BP, Goldberg RL, Chi-Rosso G., Underhill CB, Orkin RW Hyaluronate Cell Interaction. New York, NY: Alan R Liss Inc; 1984.
122. Lark MW, Culp LA Selective solubilization of hyaluronic acid from fibroblast substratum adhesive sites. J Biol Chem. 1982; 257: 14073-14080.
123. Abatangelo G., Cortivo R., Martelli M., Vecchia P. Dell detachment mediated by hyaluronic acid. Exp Cell Res. 1982; 137: 73-78.
124. Bernanke DH, Markwald RR Effects of two glycosaminoglycans on seeding of cardiac cushion tissue cells into a collagen-lattice culture system. Anat Rec. 1984; 210: 25-31.
125. Erickson CA, Turley EA Substrate formed by combinations of extracellualr matrix components alter neural crest cell motility in vitro. J Cell Sci. 1983; 61: 299-323.
126. Turley EA, Bowman P., Kytryk MA Effects of hyaluronate and hyaluronate binding proteins on cell motile and contact behaviour. J Cell Sci. 1985; 78: 133-146.
127. Feinberg RN, Beebe DC Hyaluronate in vasculogenesis. Science. 1983; 10: 1177-1179.
128. Font J., Aubery M. Inaccessibility of certain Ricinus lectin binding sites due to the increase in hyaluronic acid during chick embryo development. Differentiation. 1983; 25: 23-26.
129. Hamasima N. Effects of hyaluronic acid on the periimplantational development of mouse embros in vitro. Develop Growth Differ. 1982; 24: 353-357.
130. Toole BP, Trelstad RL Hyaluronate production and removal during corneal development in the chick. Develop Biol. 1971; 26: 28-35.
131. Schoenwolf GC, Fischer M. Analysis of the effects of Streptomyces hyaluronidase on formation of the neural tube. J Embryol Exp Morph. 1983; 73: 1-15.
132. Silberstein GB, Daniel CW Glycosaminoglycans in the basal lamina and extracellular matrix of serially aged mouse mammary ducts. Mechanisms Ageing Develop. 1984; 24: 151-162.
133. Sunderland CA, Bulmer JN, Luscombe M., Redman CWG, Stirrat GM Immunohistological and biochemical evidence for a role of hyaluronic acid in the growth and development of the placenta. J Reprod Immunol. 1985; 8: 197-212.
134. Lamberg SI, Yuspa SH, Hascall VC Synthesis of hyaluornic acid is decreased and synthesis of proteoglycans is increased when cultured mouse epidermal cells differentiate. J Invest Derm. 1986; 86: 659-667.
135. Forrester JV, Balazs EA Inhibition of phagocytosis by high molecular weight hyaluronate. Immunol. 1980; 40: 435-446.
136. Ahlgren T., Jarstrand C. Hyaluronic acid enhances phagocytosis of human monocytes in vitro. J Clin Immunol. 1984; 4: 246-249.
137. Cohn ZA, Parks E. The regulation of pinocytosis in mouse macrophages. II: factors inducing vesicle formation. J Exp Med. 1967; 125: 213-232.
138. Delmage JM, Powars DR, Jaynes PK, Allerton SE The selective supression of immunogenicity by hyaluronic acid. Ann Clin Lab Sci. 1986; 16: 303-310.
139. Sheehan KM, DeLott LB, West RA, Bonnema JD, DeHeer DH Hyaluronic acid of high molecular weight inhibits proliferation and induces cell death in U937 macrophage cells. Life Sci. 2004; 75: 3087-3102.
140. Forteza RM, Conner GE Hyaluronan and airway mucosal defense. 2002. Available at: http://www.hlycoforum.gr.jp/science/hyaluronan/HA25/HA25E.html. Accessed January 5, 2005.
141. Clarris BJ, Fraser JRE, Rodda SJ Effect of cell-bound hyaluronic acid on infectivity of Newcastle disease virus for human synovial cell in vitro. Ann Rheum Dis. 1974; 33: 240-242.
142. Trudel J., Massia SP Assessment of the cytotoxicity of photocrosslinked dextran and hyaluronan-based hydrogels to vascular smooth muscle cells. Biomaterials. 2002; 23: 3299-3307.
143. Trommer H., Warewig S., Bottcher R., et al. The effects of hyaluronan and its fragments on lipid models exposed to UV irradiation. Int J Pharm. 2003; 254: 223-224.
144. Sattar A., Rooney S., Kumar D., Pye DC, West I., Ledger P. Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin. J Invest Derm. 1994; 103: 576-579.
145. Brown TJ, Alcorn D., Fraser JRE Absorption of hyaluronan applied to the surface of intact skin. J Invest Derm. 1999; 113: 740-746.
146. Iwata Y., Akima K., Sato I., Hasegawa M. Studies of the metabolic fate of sodium hyaluronate (SL-1010) (IV): transfer into the fetus, and excretion into milk and bile after intravenous administration of SL-1010 in rats [in Japanese]. Yakuri To Chiryo. 1991; 19: 379-389.
147. Laurent UBG, Fraser JRE, Laurent TC An experimental technique to study the turnover of concentrated hyaluronan in the anterior chamber of the rabbit. Exp Eye Res. 1988; 46: 49-58.
148. Lebel L., Fraser JRE, Kimpton WS, Gabrielsson J., Berdin B., Laurent TC A pharmacokinetic model of intravenously adminstered hyaluronan in sheep. Pharm Res. 1989; 6: 677-682.
149. Laurent UBG, Fraser JRE Disappearance of concentrated hyaluronan from the anterior chamber of monkey eyes. Exp Eye Res. 1990; 51: 65-69.
150. Allen SR, Fraser FRE, Laurent UBG, Reed RK, Laurent TC Turnover of hyaluronan in the rabbit pleural space. J Appl Physiol. 1992; 73: 1457-1460.
151. Edelstam GAB, Laurent UBG, Lundkvist ÖE, Fraser JRE, Laurent TC Concentration and turnover of intraperitoneal hyaluronan during inflammation. Inflammation. 1992; 16: 459-469.
152. Scuri M., Abraham WM Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulmonary Pharm Therapeutics. 2003; 16: 335-340.
153. Surendrakumar K., Martyn GP, Hodgers ECM, Jansen M., Blair JA Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Controlled Release. 2003; 91: 385-394.
154. Bousquet M-T., Ågerup B. Restylane lip implantation. European experience. Oper Techniq Ocul Orbital Recon Surg. 1999; 2: 172-176.
155. FDA Summary of safety and effectiveness data: Deflux. 2001. http://www.fda.gov/cdrh/mda/docs/p000029.html. Accessed January 5, 2005.
156. Humphrey JH Antigenic properties of hyaluronic acid. Biochem J. 1943; 37: 460-463.
157. Quinn RW, Singh KP Antigenicity of hyaluronic acid. Proc Soc Exp Biol Med. 1957; 95: 290-294.
158. Hammerman D., Sandson J. Immunologic cross-reactions between streptococcal hyaluronic acid and proteoglycans of human connective tissue. In: Balazs EA, ed. Chemistry and Molecular Biology of the Intercellular Matrix. London: Academic Press; 1970;3: 1537-1549.
159. Richter AW Non-immunogenicty of purified hyaluronic acid preparation tested by passive cutaneous anaphaxis. Int Arch Allergy Appl Immunol. 1974; 47: 211-217.
160. Uhlin A., Richter W., Björkstén B. Enhanced humoral immune response in rats by hyaluronic acid. Int J Immynopharmacol. 1982; 4: 529-532.
161. Goomer RS, Leslie K., Maris T., Amiel D. Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Related Res. 2005; 434: 239-245.
162. Anniko M., Hellström S., Laurent C. Reversible changes in inner ear functions following hyaluronan application in the middle ear. Acta Otolaryngol (Stoch). 1987;Suppl 442: 72-75.
163. Bjurström B., Slepeck N., Angelborg C. A histopathological study of the inner ear after the adminstration of hyaluronan into the middle ear of the guinea pig. Acta Otolaryngol (Stoch). 1987;Suppl 442: 62-65.
164. Engström B., Bjurström S., Jansson B., Engström H., Angelborg C. An ultrastructural and functional study of the inner ear after adminstration of hyaluronan into the middle ear of the guinea pig. Acta Otolaryngol (Stoch). 1987; 442: 66-71.
165. Lim Y.-J, Sim W.-S, Kim Y.-C, Lee S.-C, Choi Y.-L. The neurotoxicity of epidural hyaluronic acid in rabbits: a light and electron microscopic examination. Anesth Analg. 2003; 97: 1716-1720.
166. Furuhashi T., Takei A., Nakayoshi H. Reproduction studies of sodium hyaluronate (SPH) (4) perinatal and postnatal test in rats [in Japanese]. NRI Life Sci. 1985; 29: 139-153.
167. Wada K., Hashimoto Y., Mizutani M., Tanaka C. Reproductive and developmental toxicity studies of sodium hyaluronate (SL-1010) (III) [in Japanese]. Jpn Pharmocol Ther. 1991; 19: 111-119.
168. Tateda C., Nagaoka S., Nagai T., Nakamura T. Reproductive and developmental toxicity study (IV) on sodium hyaluronate (SH) (4): study on subcutaneous administration to rabbits during organogenesis period [in Japanese]. Jpn Pharmocol Ther. 1992; 20: 51-58.
169. Matsuura T., Nakajima H., Maeda H., et al. Teratological study of high molecular weight sodium hyaluronate (NRD101) in rabbits [in Japanese]. Yakuri To Chiryo. 1994; 22: 205-213.
170. Sugiyama C., Yagame O. Mutagenicity studies of sodium hyaluronate (SL-1010). I: reverse mutation test on bacteria [in Japanese]. Jpn Pharmocol Ther. 1991; 19: S177-S181.
171. Aruga F., Miwa Y., Fuzimura T., Ohata S. Micronucleus test of sodium hyaluronate (SH) using mice [in Japanese]. Jpn Pharmocol Ther. 1992; 20: 775-777.
172. Onishi M., Nagata T., Saigou K., Sameshima H., Nagata R. Mutagenicity studies of sodium hyaluronate (SH) [in Japanese]. Yakuri To Chiryo. 1992; 20: 767-774.
173. Aruga F., Nagasawa Y., Miwa Y., Tanaka R., Sugiyama H., Ota S. Mutagenicity test of high molecular weight sodium hyaluronate (NRD101) [in Japanese]. Yakuri To Chiryo. 1994; 22: S627-S636.
174. McBride WH, Bard JBL Hyaluronidase-sensitive halos around adherent cells: their role in blocking lymphocyte-mediated cytolysis. J Exp Med. 1979; 149: 507-515.
175. Asplund T., Versnel MA, Laurent TC, Heldin P. Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts. Cancer Res. 1993; 53: 388-392.
176. Zhang L., Underhill CB, Chen L. Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res. 1995; 55: 428-433.
177. Li Y., Heldin P. Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer. 2001; 85: 600-607.
178. Enegd B., King JAJ, Stylli S., Paradiso L., Kaye AH, Novak U. Overexpression of hyaluronan synthase-2 reduces the turmorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery. 1992; 50: 1311-1318.
179. Ghatak S., Misra S., Toole BP Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem. 2002; 277: 38013-38020.
180. Jacobson A., Rahmanian M., Rubin K., Heldin P. Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer. 2002; 102: 212-219.
181. Udabage L., Brownlee GR, Waltham M., et al. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the turmorigenesis and progression of breast cancer. Cancer Res. 2005; 65: 6139-6150.
182. Sugahara K., Hirata T., Hayasaka H., Stern R., Murai T., Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006; 281: 5861-5868.
183. Shuster S., Frost GI, Csóka AB, Formby B., Stern R. Hyaluronidase reduces human breast cancer zenografts in SCID mice. Int J Cancer. 2002; 102: 192-197.
184. Misra S., Ghatak S., Zoltan-Jones A., Toole BP Regulation of multi-drug resisitance in cancer cells by hyaluronan. J Biol Chem. 2003; 278: 25285-25288.
185. Wang SJ, Bourguignon LYW Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006; 132: 19-24.
186. Yin D., Ge Z., Yang W., Liu C., Yuan Y. Inhibition of tumor metastasis in vivo by combination of paclitaxel and hyaluronic acid. Cancer Letters. 2006; 243: 71-79.
187. Laugier J-P., Shuster S., Rosdy M., Csóka AB, Stern R., Maibach HI Topical hyaluronidase decreases hyaluronic acid and CD44 in human skin and in reconstituted human epidermis: evidence that hyaluronidase can permeate the stratum corneum. Br J Dermatol. 2000; 142: 226-233.
188. Fraser JRE, Appelgren L-E., Laurent TC Tissue uptake of circulating hyaluronic acid: a whole body autoradiographic study. Cell Tissue Res. 1983; 233: 285-293.
189. Engström-Laurent A., Laurent UBG, Lilja K., Laurent TC Concentration of sodium hyalruonate in serum. Scand J Clin Lab Invest. 1985; 45: 497-504.
190. Fraser JRE, Kimpton WG, Laurent TC, Cahill RNP, Vakakis N. Uptake and degradation of hyaluronan in lymphatic tissue. Biochem J. 1988; 256: 153-158.
191. Fraser JRE, Laurent TC, Pertoft H., Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J. 1981; 200: 415-424.
192. Fraser JRE, Laurent TC, Engström-Laurent A. Elimination of hyaluronic acid from the bloodstream in the human. Clin Exp Pharmacol Physiol. 1984; 11: 17-25.
193. Smedsrød B., Pertoft H., Eridsson S., Fraser JRE, Laurent TC Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J. 1984; 223: 617-626.
194. Fraser JRE, Alcorn D., Laurent TC, Robinson AD, Ryan GB Uptake of circulating hyaluronic acid by the rat liver: cellular localization in situ. Cell Tissue Res. 1985; 242: 505-510.
195. Rodén L., Campbell P., Fraser JRE, Laurent TC, Pertoft H., Thompson JN Enzymic pathways of hyaluronan catabolism. Ciba Found Symp. 1989; 143: 60-86.
196. Laurent TC, Fraser JRE Hyaluronan. FASEB J. 1992; 6: 2397-2404.
197. Deguine V., Menasche M., Ferrari P., Fraisse L., Pouliquen Y., Rober L. Free radical depolymerization of hyaluronan by Maillard reaction products: roe in liquefaction of aging vitreous. Int J Biol Macromol. 1998; 22: 17-22.
198. Ågren UM, Tammi RH, Tammi MI Reactive oxygen species contribute to epidermal hyaluronan catobolism in human skin organ culture. Free Radic Biol Med. 1997; 23: 996-1001.
199. Engström-Laurent A., Lööf L., Nyberg A., Schröder T. Increased serum levels of hyaluronate in liver disease. Hepatology. 1985; 5: 638-642.
200. Fraser JRE, Engström-Laurent A., Nyberg A., Laurent TC Removal of hyaluronic acid from circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med. 1986; 107: 79-85.
201. Gibson PR, Fraser JRE, Brown TJ, et al. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology. 1992; 15: 1054-1059.
202. Engström-Laurent A., Hällgren R. Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis. 1985; 44: 83-88.
203. Homicz MR, Watson D. Review of infectable material for soft tissue augmentation. Facial Plastic Surg. 2004; 20: 21-29.
204. Draelos ZD The use of biological additives in cosmetic products: part 1. Cosmetic Derm. 1994; 7: 16-17.
205. Brown MB, Marriot C., Martin GP The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int J Tissue Reac. 1995; 17: 133-140.
206. Brown MB, Ingham S., Moore A., et al. A Preliminary Study of the Effect of Hyaluronan in Drug Delivery. London, England: Royal Society of Medicine Press; 1995.
207. Lin W., Maibach HI Percutaneous Absorption of Diclofenac in Hyaluronic Acid Gel: In Vitro Study in Human Skin. London, England: Royal Society of Medicine Press; 1996.
208. Brown MB, Hanpanitcharoen M., Martin GP An in vitro investigation into the effect of glycosaminoglycans on the skin partitioning and deposition of NSAIDs. Int J Pharm. 2001; 225: 113-121.
209. Brown MB, Forbes B., Martin GP The Use of Hyaluronan in Tropical Delivery. Cambridge, England: Woodhead Publisher s; 2002.
210. Amr SK The effect of homogenised skin on the activity of licosamide antibiotics. Paper presented at: Proceedings of Millennium Congress of Pharmaceutical Science; April 16-20, 2000; San Francisco, CA.
211. Brown MB, Moore A. The Effects of a Novel Formulation of Cyclosporin on Antibody and Cell-Mediated Immune Reactions in the Pleural Cavity of Rats. London, England: Royal Society of Medicine Press; 1996.
212. Mazir T., Martin GP, Brown MB Dermal delivery cyclosporin A entrapped liposomal gells: preformulation Franz Cell diffusion studies using silastic membranes. STP Pharm. 2001; 3: 1429.
213. Jarvis B., Figgitt DP Topical 3% dicolfenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Amer J Clin Dermatol. 2003; 4: 203-213.
214. De La Motte CA, Hascall VC, Calabro A., Yen-Leiberman B., Strong SA Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with poly(I.C.). J Biol Chem. 1999; 274: 30747-30755.
215. De La Motte CA, Hascall VC, Drazba J., Bandyopadhyay SK, Strong SA Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid: polycytidylic acid. Amer J Path. 2003; 163: 121-133.
216. Maytin EV, Chung HH, Seetharaman VM Hyalronan participates in the epidermal response to disruption of the permeability barrier in vivo. Amer J Path. 2004; 165: 1331-1341.
217. Engström-Laurent A., Hallgren R. Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients: relationship to synovitis mass and morning stiffness. Arthritis Rheum. 1987; 30: 1333-1338.
218. Lundin A., Engström-Laurent A., Hallgren R., Michaelsson G. Circulating hyaluronate in psoriasis. Br J Dermatol. 1985; 112: 663-671.
219. Berg S., Brodin B., Hesselvik F., Laurent TC, Maller R. Elevated levels of plasma hyaluronan in septicaemia. Scand J Clin Lab Invest. 1988; 48: 727-732.
220. Håkansson L., Hällgren R., Venge P. Regulation of granulocyte function by hyaluronic acid: in vitro and in vivo effects on phagocytosis, locomotion, and metabolism. J Clin Invest. 1980; 66: 298-305.
221. Tammi R., Paukkonen K., Wang C., Horsmanheimo M., Tammi M. Hyaluronan and CD44 in psoriatic skin, intense staining for hyaluronan on dermal capillary loops and reduced expression of CD44 and hyaluronan in keratinocyte-leukocyte interfaces. Arch Dermatol Res. 1994; 286: 21-29.
222. Richter AW, Ryde EM, Zetterström EO Non-immunogenicity of a purified sodium hyaluronate preparation in man. Int Arch Allergy Appl Immunol. 1979; 59: 45-48.
223. Altman RD, Åkermark Bearleiu AD, Schnitzer T. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2004; 12: 642-649.
224. Neustadt DH Long-term efficacy and safety of intraarticular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol. 2003; 21: 307-311.
225. Chen AL, Desai P., Adler E., De Cesare PE Granulomatous inflammation after hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg. 2002; 84A: 1142-1147.
226. Olenius M. The first clinical study using a new biodegradable implant for the treatment of lips, wrinkles, and folds. Aesth Plast Surg. 1998; 22: 97-101.
227. Lowe NJ, Maxwell CA, Lowe P., Duick MG, Shah K. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol. 2001; 45: 930-933.
228. Friedman PM, Mafong EA, Dauvar ANB, Geronems RG Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg. 2002; 28: 491-494.
229. André P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA-Q-Medical, Sweden) in European countries: a retrospective study from 1997 to 2001. J Eur Acad Dermatol Venerol. 2004; 18: 422-425.
230. Toole BP Mini review: hyaluronan promotes the malignant phenotype. Glycobiology. 2002; 12: 37R-42R.
231. Auvinen P., Tammi R., Parkkinen J., et al. Hyaluronan in periturmoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Amer J Path. 2000; 156: 529-536.
232. Gately CL, Muul LM, Greenwood MA, et al. In vitro studies on the cell-mediated immune response to human brain tumors. II: leucocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J Immunol. 1984; 133: 3387-3395.
233. Setälä LP, Tammi MI, Tammi RH, et al. Hyaluronan expression in gastric cancer cells is associated with the local and nodal spread and reduced survival rate. Br J Cancer. 1998; 79: 1133-1138.
234. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma V.-M. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 2000; 60: 150-155.
235. Stenvinkel P., Heimbürger O., Wang T., Lindholm B., Bergström J., Elinder C-G. High serum hyaluronan indicates poor survival in renal replacement therapy. Amer J Kidney Dis. 1999; 34: 1083-1088.
236. Zeng C., Toole BP, Kinney SD, Kuo J.-W. Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer. 1998; 77: 396-401.
237. Toole BP Hyaluronan: from extracellular glue to pericellular cue. Nature Rev. 2004; 4: 528-539.
238. Bracey AW, Wu AHB, Aceves J., Chow T., Carlile S., Hoots WK Platelet dysfunction associated with Wilm's tumor and hyaluronic acid. Am J Hematol. 1987; 24: 247-257.
239. Heldin P., Laurent TC, Heldin C.-H. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem J. 1989; 258: 919-922.
240. Fraizer GE, Bowen-Pope DF, Vogel AM Production of platelet-derived growth factor by cultured Wilms' tumor cells and fetal kidney cells. J Cell Physiol. 1987; 133: 169-174.
241. Deutsch HF Some properties of a human serum hyaluronic acid. J Biol Chem. 1957; 224: 767-774.
242. Tomasi TB, Van B., Roberson W., Naeye R., Reichlin M. Serum hyperviscosity and metabolic acidosis due to circulating hyaluronic acid. J Clin Invest. 1966; 45: 1080-1081.
243. Morse BS, Nussbaum M. The detection of hyaluronic acid in the serum and urine of a patient with nephroblastoma. Am J Med. 1967; 42: 966-1002.
244. Allerton SE, Beierle JW, Powars DR, Bavetta LA Abnormal extracellular components in Wilm's tumor. Cancer Res. 1970; 30: 679-683.
245. Wu AHB, Parker OS, Ford L. Hyperviscosity caused by hyaluronic acid in serum in a case of Wilms' tumor. Clin Chem. 1984; 30: 914-916.
246. Longaker MT, Adzick NS, Sadigh D., et al. Hyaluronic acid-stimulating activity in the pathophysiology of Wilms' tumors. J Nat Cancer Inst. 1990; 82: 195-199.
247. Kumar S., West DC, Ponting JM, Gattameaeni HR Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer. 1989; 44: 445-448.
248. Kumar S., West DC, Ponting JM Hyaluronic acid and childhood renal tumours. J Nat Cancer Inst. 1990; 82: 973-974.
249. Meyer K., Chaffe E. Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum. J Biol Chem. 1940; 133: 83-91.
250. Roboz J., Greaves J., Lilides D., Chahinian AP, Holland JF Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. J Cancer Res. 1985; 45: 1850-1854.
251. Frebourg T., Lerebours G., Delpech B., et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer J. 1987; 59: 2104-2107.
252. Dahl IMS, Solheim P., Erikstein B., Müller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Cancer. 1989; 64: 68-73.
253. Chevrier A., Girard B., Delpech B., Gilbert D. Inhibition of active E rosette forming T lymphocytes by hyaluronic acid: evidence of a receptor for hyaluronic acid on a lymphocyte subpopulation. Biomedicine. 1982; 36: 100-103.
254. Stern R. Hyaluronan metabolism: a major paradox in cancer biology. Pathologie Biologie. 2005; 53: 372-382.
255. Cooper EH, Forbes MA Serum hyaluronic acid levels in cancer. Br J Cancer. 1988; 58: 668-669.
256. Dahl IMS, Laurent TC Concentration of hyaluronan in the serum of untreated cancer patients with special reference to patients with mesothelioma. Cancer. 1988; 62: 326-330.
257. Schüller J., Fogl U., Bosse CH, Schernthaner G. Serum hyaluronic acid levels in cancer patients with different tumor types. Abstract presented at: Sixth International Conference on Differentiation of Normal Neoplastic Cells; July 20-August 2 1990; Vancouver, Canada.
258. Delpech B., Chevallier B., Reinhardt N., et al. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer. 1990; 46: 388-390.
259. Ponting J., Howell A., Pye D., Kumar S. Prognostic relevance of serum hyaluronan levels in patients with breast cancer. Int J Cancer. 1992; 52: 873-876.
260. Abildgaard N., Lanng Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide and hyaluronan. Am J Hematol. 1994; 46: 173-178.
261. Pauli BU, Knudson W. Tumor invasion: a consequence of destructive and compositional matrix alterations. Human Path. 1988; 19: 628-639.
262. Hedman M., Arnberg H., Wernlund J., Riska H., Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003; 23: 531-536.
263. Karvinen S., Kosma V.-M, Tammi MI, Tammi R. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol. 2003; 148: 86-94.
264. Yabushita H., Kishida T., Fusano K., et al. Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncology Reports. 2005; 131: 101-105.
265. Boregowda RK, Appaiah HN, Siddaiah M., et al. Expression of hyaluronan in human tumor progression. J Carcinog. 2006; 5: 2.
266. Carte MD, González LO, Luz Lamelas M., et al. Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res Treatment. 2006; 97: 329-337.
267. Ali Y., Weinstein M., Jokl P. Acute pseudogout following intra-articular injection of high molecular weight hyaluronic acid. Amer J Med. 1999; 107: 641-642.
268. Allen E., Krohn K. Adverse reactions to hylan G-F 20. J Rheumotol. 2000; 27: 6.
269. Lupton JR, Alster TS Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg. 2000; 26: 135-137.
270. Raulin C., Greve B., Hartschuh W., Soegding K. Exudative granulomatous reaction to hyaluronic acid (Hylaform). Contact Dermatitis. 2000; 43: 178-179.
271. Bernardear C., Bucki B., Lioté F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann Rheum Dis. 2001; 60: 518-520.
272. Kavouni A., Stanec JJ Human antihyaluronic acid antibodies. Dermatol Surg. 2002; 28: 359-360.
273. Hönig JF, Brink U., Korabiowska M. Severe granulomatous allergic tissue reaction after hyaluronic acid injection in the treatment of facial lines and its surgical correction. J Craniofacial Surg. 2003; 14: 197-200.
274. Lombardi T., Samson J., Plantier F., Husson C., Küffer R. Orofacial granulomas after injection of cosmetic fillers: histopathologic and clinical study of 11 cases. J Oral Pathol Med. 2004; 33: 115-120.
275. Jordan DR Delayed inflammatory reaction to hyaluronic acid (Restylane). Ophthal Plastic Reconstr Surg. 2005; 21: 401-402.
276. Patel VJ, Bruck MC, Katz BE Hypersensitivity reaction to hyaluronic acid with negative skin testing. Plastic Reconstructive Surg. 2006; 117: 92e-94e.
277. Brown MB, Jones SA Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venerol. 2005; 19: 308-318.
278. Rosato A., Banzato A., De Luca G., et al. HYTADI-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol Sem Orig Invest. 2006; 24: 207-215.
279. Goa KL, Benfield P. Hyaluronic acid: a review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease. Drugs. 1994; 47: 536-566.
280. Laurent TC "The tree": hyaluronan research in the 20th century. 2002. Available at: http://www.glcoforum.gr.jp/science/hyaluronan/HA23/HA23E.html. Accessed January 5, 2005.
281. Ota R., Hashimoto Y., Matsumoto A., Mizutani M., Tanaka C. Reproductive and developmental toxicity studies of sodium hyaluronate (SL01010) (IV): perinatal and postnatal study in rats [in Japanese]. Yakuri To Chiryo. 1991; 19: 121-135.
282. Tanaka C., Sasa H., Hirama S., et al. Reproductive and developmental toxicity studies of sodium hyaluronate (SL-1010) (I): adminstration test in rats before pregnancy and in early stage of pregnancy [in Japanese]. Jpn Pharmocol Ther. 1991; 19: 81-92.
283. Tanaka C., Sasa H., Hirama S., et al. Reproductive and developmental toxicity studies of sodium hyaluronate (SL-1010) (II): teratogencity study in rats (study on administration during the period of fetal organogenesis in rats) [in Japanese]. Jpn Pharmocol Ther. 1991; 19: 93-110.
284. Ono C., Iwama A., Nakajima Y., Kitsuya A., Nakumura T. Reproductive and developmental toxicity studies on sodium hyaluronate (SH) (I): study on subcutaneous administration to rats during the period of organogenesis [in Japanese]. Yakuri To Chiryo. 1992; 20: 11-26.
285. Ono C., Fufiwara Y., Koura S. Reproductive and developmental toxicity study on sodium hyaluronate (SH) (2): study on subcutaneous administration to rats prior to and in the early stages of pregnancy [in Japanese]. Yakuri To Chiryo. 1992; 20: 27-35.
286. Ono C., Ishitobi H., Kozuka K., Konagai S., Nakamura T. Reproductive and developmental toxicity study (III): on sodium hyaluronate (SH) [in Japanese]. Yakuri To Chiryo. 1992; 20: 37-50.
287. Matsuura T., Nakajima H., Maeda H., et al. Teratological study of high molecular weight sodium hyaluronate (NRD101) in rats [in Japanese]. Yakuri To Chiryo. 1994; 22: 185-203.
288. Matsuura T., Nakajima H., Aeda H., et al. Perinatal and postnatal study of high molecular weight sodium hyaluronate (NRD101) in rats [in Japanese]. Yakuri To Chiryo. 1994; 22: 215-233.
289. Hattori M., Inoue S., Ogura H., et al. Reproductive and developmental toxicity study of a 1% solution sodium hyaluronate (SI-4402). 1: fertility study in rats by subcutaneous administration [in Japanese]. Oyo Yakuri. 1995; A50: 93-103.
290. Kumada J., Nishiwaki K., Iriyama K., et al. Reproductive and developmental toxicity study of a 1% solution of sodium hyaluronate (SI-4402) [in Japanese]. Oyo Yakuri. 1995; 50: 105-122.
291. Carrabba M., Paresce E., Angelini M., Re KA, Torchiana EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm. 1995; 15: 25-31.
292. Bragantini AM, Cassini M., DeBastiani B., Perebellini A. Controlled single-blind trial of intraarticularly-injected hyaluronic acid (Hyalgan) in osteoarthritis of the knee. Clin Trial J. 1987; 24: 333-341.
293. Grecomoro G., Martorana U., DiMarco C. Intraarticular treatment with sodium hyaluronate in gonarthrosis: a controlled clincal trial versus placebo. Pharmacotherapeutica. 1987; 5: 137-141.
294. Dixon ASF, Jacoby RK, Berry H., Hamiton EBD Clinical trial of intraarticular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin. 1988; 11: 205-213.
295. Dougados M., Mguyen M., Listrat V., Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage. 1993; 1: 97-103.
296. Henderson EB, Smith EC, Pegley F., Blake DR Intraarticular injections of 750 kDa hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis. 1994; 53: 529-534.
297. Corrado EM, Peluso GF, Gigliotti S., et al. The effects of intra-articular administration of hyaluronic acid on osteoarthritis of the knee: a clinical study with immunological and biochemical evaluations. Eur J Rheumatol Inflamm. 1995; 15: 47-56.
298. Listrat V., Ayral X., Patarnello F., et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage. 1997; 5: 153-160.
299. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. J Rheumatol. 1998; 25: 2203-2212.
300. Huskisson EC, Donnelly S. Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology. 1999; 38: 602-607.
301. Wobig M., Dickhut A., Maier R., Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther. 1998; 20: 410-423.
302. Puhl W., Bernau A., Greiling H., et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage. 1993; 1: 233-241.
303. Dahlberg L., Lohmander LS, Ryd L. Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. Arthritis Rheum. 1994; 37: 521-528.
304. Lohmander LS, Dalén N., Englund G., et al. Intraarticular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Ann Rheum Dis. 1996; 55: 424-431.
305. Wu J-J., Shih L.-Y, Hsu H.-C, Chen T.-H. The double-blind test of sodium hyaluronate (ARTZ) on osteoarthritic knees. Chin Med J (Taipei). 1997; 59: 99-106.